Clinical stage antimicrobials that address AMR
Product or Service Two phase 3 ready antibacterial assets which prevent infection
Both products address AMR and spare antibiotic use
- Infection prevention
- Antimicrobial compound/strategy
- License, Co-develop, Outsource, Joint Venture, Sell
- OTHER / NA
Infectious disease area:
National territory and global licensing rights deals will be considered for phase 3 ready assets. Partner capable of supporting product development through phase 3 to approval and marketing within the relevant territory.
Clinical stage, UK based, biotechnology company focused on novel antimicrobials that prevent and treat infection
Preclinical: SPOR-COV immune boosting biotherapeutic for the prevention of viral respiratory infection, COVID-19. XF 73 dermal, treatment of bacterial skin infections. XF drug based bacterial biofilm active approaches.